<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701207</url>
  </required_header>
  <id_info>
    <org_study_id>2008H0006</org_study_id>
    <secondary_id>S-07-006</secondary_id>
    <nct_id>NCT00701207</nct_id>
  </id_info>
  <brief_title>Study of Nicotine Patches in Patients With Sarcoidosis</brief_title>
  <official_title>Modulation of Pulmonary Sarcoidosis by Nicotinic Acetylcholine Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elliott Crouser MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Thoracic Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare peoples with disease (sarcoidosis) to those without&#xD;
      disease. We want to see if people with sarcoidosis have a different immune response to those&#xD;
      people without disease.&#xD;
&#xD;
      The goal of this study is to see if the nicotine patch is an anti-inflammatory treatment for&#xD;
      sarcoidosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Until recently, there was no good explanation for the fact that smoking cigarettes actually&#xD;
      reduces the risk of sarcoidosis. Research studies have shown that the nicotine, a common&#xD;
      component of cigarette smoke, strongly suppresses the immune system and reduces the type of&#xD;
      inflammation that is characteristic of sarcoidosis in the lungs. We propose that nicotine&#xD;
      treatment, administered in the form of a skin patch, will reduce the severity of lung disease&#xD;
      in patients with sarcoidosis. Sarcoidosis patients who volunteer to participate in this study&#xD;
      will submit standardized questionnaires relating to their quality of life and the severity of&#xD;
      their shortness of breath before and after treatment. We will also compare objective measures&#xD;
      of lung function, radiographic parameters, and the severity of lung inflammation. We predict&#xD;
      that nicotine treatment will reduce the severity of sarcoidosis symptoms, improve lung&#xD;
      function, and resolve lung inflammation. If our hypothesis is proven to be correct in this&#xD;
      relatively small group of patients, we will perform additional studies in a larger group of&#xD;
      patients and will consider the features of sarcoidosis patients that predict a favorable&#xD;
      response to nicotine and other nicotine-like drugs. If nicotine is ultimately found to be an&#xD;
      effective treatment for sarcoidosis, it may replace some of the existing treatments which are&#xD;
      frequently ineffective and have unacceptable side-effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 31, 2010</completion_date>
  <primary_completion_date type="Actual">December 31, 2010</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if nicotine treatment reduces lung inflammation.</measure>
    <time_frame>3 months</time_frame>
    <description>Normalization of immune response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if expression of α7 nAChR on monocytes/macrophages derived from the blood/lungs correlates with the severity of pulmonary sarcoidosis.</measure>
    <time_frame>3 months</time_frame>
    <description>Improvement in FVC</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Pulmonary Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>2.</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group-no intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy control group-blood and sputum samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nicotine patch; transdermal patch 7mg, 14 mg., 21 mg. 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotine patch</intervention_name>
    <description>daily transdermal patch 7 mg, 14mg, 21 mg. 3 months</description>
    <arm_group_label>1.</arm_group_label>
    <other_name>Habitrol QC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Symptomatic (active) granulomatous lung disease (radiographic stage II or III&#xD;
             disease) at least 6 months after the diagnosis. This selects patients that have the&#xD;
             chronically active variant of sarcoidosis and will likely require long-term treatment&#xD;
             (33).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Active smokers,&#xD;
&#xD;
               -  Previous splenectomy,&#xD;
&#xD;
               -  Those requiring high-dose immunosuppression [i.e., ≥ 0.2 mg/kg/day prednisone (or&#xD;
                  equivalent) or &gt; 10 mg/week methotrexate or requires second line cytolytic agents&#xD;
                  (e.g., cyclophosphamide, azathioprine) or anti-TNF treatments (e.g., thalidomide,&#xD;
                  anti-TNF antibodies, etc.)] to control disease activity.&#xD;
&#xD;
               -  We will also exclude patients at high risk of complications relating to the use&#xD;
                  of nicotine. This will include patients with a known intolerance of nicotine or&#xD;
                  those with active cardiac or central nervous system disease who are at higher&#xD;
                  risk of cardiac arrhythmias or seizures.&#xD;
&#xD;
               -  We will also exclude patients with extensive pulmonary fibrosis based upon lung&#xD;
                  biopsy or high resolution CT scan criterion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliott D. Crouser, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Julian MW, Shao G, Schlesinger LS, Huang Q, Cosmar DG, Bhatt NY, Culver DA, Baughman RP, Wood KL, Crouser ED. Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis. Chest. 2013 Feb 1;143(2):461-470. doi: 10.1378/chest.12-0383.</citation>
    <PMID>22878868</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 17, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Elliott Crouser MD</investigator_full_name>
    <investigator_title>Medical Director, Intensive Care Unit, UHE</investigator_title>
  </responsible_party>
  <keyword>To determine if nicotine treatment reduces lung inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis, Pulmonary</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

